Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$2.59 +18.3%	$1.46	$0.40 ▼ $2.82	$43.98M	0.18	315,091 shs	809,352 shs
BCEL Atreca	$0.09	$0.09	$0.05 ▼ $1.20	$3.57M	1.03	4.61 million shs	N/A
GLYC GlycoMimetics	$0.16 -6.6%	$18.40	$14.06 ▼ $63.00	$10.00M	1.62	63,887 shs	1.05 million shs
NRSN NeuroSense Therapeutics	$1.90 -4.0%	$1.58	$0.51 ▼ $2.60	$25.97M	1.61	279,708 shs	566,342 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	0.00%	+40.76%	+93.28%	+144.34%	+234.63%
BCEL Atreca	0.00%	0.00%	0.00%	0.00%	0.00%
GLYC GlycoMimetics	0.00%	0.00%	-99.26%	-99.26%	-99.45%
NRSN NeuroSense Therapeutics	0.00%	-19.15%	+24.18%	+104.32%	+69.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVC ABVC BioPharma	0.3387 of 5 stars	0.0	3.0	0.0	0.0	1.9	0.8	0.0
BCEL Atreca	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GLYC GlycoMimetics	1.8242 of 5 stars	0.0	3.0	0.0	4.6	3.3	1.7	0.0
NRSN NeuroSense Therapeutics	2.2852 of 5 stars	3.5	3.0	0.0	0.0	2.2	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	0.00	N/A	N/A	N/A
BCEL Atreca	0.00	N/A	N/A	N/A
GLYC GlycoMimetics	2.50	Moderate Buy	N/A	N/A
NRSN NeuroSense Therapeutics	3.00	Buy	$14.00	636.84% Upside

Current Analyst Ratings Breakdown

Latest BCEL, GLYC, ABVC, and NRSN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/12/2025	NRSN NeuroSense Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	86.23	N/A	N/A	$0.06 per share	43.17
BCEL Atreca	N/A	N/A	N/A	N/A	$2.01 per share	N/A
GLYC GlycoMimetics	$10K	1,000.25	N/A	N/A	$0.08 per share	1.94
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	$0.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$4.90M	-$0.13	N/A	∞	N/A	-963.46%	-29.62%	-14.08%	8/13/2025 (Estimated)
BCEL Atreca	-$97.16M	-$2.50	N/A	N/A	N/A	N/A	-157.90%	-71.39%	N/A
GLYC GlycoMimetics	-$37.88M	-$0.46	N/A	N/A	N/A	N/A	-230.74%	-177.39%	8/6/2025 (Estimated)
NRSN NeuroSense Therapeutics	-$10.21M	-$0.54	N/A	∞	N/A	N/A	N/A	-445.40%	N/A

Latest BCEL, GLYC, ABVC, and NRSN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	GLYC GlycoMimetics	-$5.00	-$4.00	+$1.00	-$0.04	N/A	N/A
4/30/2025	Q4 2024	ABVC ABVC BioPharma	N/A	-$0.06	N/A	-$0.06	N/A	N/A
4/15/2025	Q4 2024	ABVC ABVC BioPharma	N/A	$0.04	N/A	$0.04	N/A	N/A
4/7/2025	Q4 2024	NRSN NeuroSense Therapeutics	-$0.12	-$0.06	+$0.06	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
BCEL Atreca	N/A	N/A	N/A	N/A	N/A
GLYC GlycoMimetics	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.22	0.22
BCEL Atreca	N/A	1.58	1.58
GLYC GlycoMimetics	N/A	1.92	1.92
NRSN NeuroSense Therapeutics	N/A	2.21	2.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
BCEL Atreca	37.47%
GLYC GlycoMimetics	75.19%
NRSN NeuroSense Therapeutics	1.04%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	17.10%
BCEL Atreca	11.30%
GLYC GlycoMimetics	8.70%
NRSN NeuroSense Therapeutics	27.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	16.98 million	14.08 million	Not Optionable
BCEL Atreca	130	39.62 million	35.15 million	Optionable
GLYC GlycoMimetics	50	64.53 million	58.90 million	Optionable
NRSN NeuroSense Therapeutics	10	13.67 million	9.92 million	Not Optionable

BCEL, GLYC, ABVC, and NRSN Headlines

Recent News About These Companies

NeuroSense Completes Key Meeting with Health Canada for ALS Drug Approval

June 26, 2025 | tipranks.com

Top Nasdaq Companies by Market Cap Ranked by Kalkine

June 7, 2025 | kalkinemedia.comK

Neurosense, awaiting Canada approval, scales PrimeC production

May 15, 2025 | alsnewstoday.comA

D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation

May 14, 2025 | msn.com

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 12, 2025 | benzinga.com

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025 | prnewswire.com

NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership

April 24, 2025 | tipranks.com

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

April 24, 2025 | prnewswire.com

NeuroSense Therapeutics Presents Promising Phase 2b Data on PrimeC for ALS at AAN Meeting

April 10, 2025 | sohu.comS

NeuroSense Therapeutics Reports Year-End 2024 Financial Results and Provides Business Updates

April 10, 2025 | sohu.comS

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

April 9, 2025 | prnewswire.com

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

April 7, 2025 | prnewswire.com

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

April 4, 2025 | prnewswire.com

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

March 20, 2025 | businesswire.com

NeuroSense Advances PrimeC Commercialization in Canada

March 19, 2025 | tipranks.com

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

March 17, 2025 | businesswire.com

Life Saving Innovation in Neurodegenerative Disease Treatment: An Interview with Alon Ben-Noon, CEO & Founder of NeuroSense Therapeutics

March 12, 2025 | techbullion.comT

NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment

February 19, 2025 | tipranks.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Elevance Health (ELV) and Genmab (GMAB)

February 4, 2025 | markets.businessinsider.com

NeuroSense regains Nasdaq compliance

January 8, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCEL, GLYC, ABVC, and NRSN Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$2.59 +0.40 (+18.26%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.65 +0.06 (+2.36%)

As of 05:21 AM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Atreca NASDAQ:BCEL

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

GlycoMimetics NASDAQ:GLYC

$0.16 -0.01 (-6.63%)

Closing price 06/13/2025

Extended Trading

$0.16 0.00 (0.00%)

As of 06/13/2025 07:49 PM Eastern

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

NeuroSense Therapeutics NASDAQ:NRSN

$1.90 -0.08 (-4.04%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.08 +0.18 (+9.47%)

As of 04:00 AM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time